SUN Lakes Dialysis (FMC) is a medicare approved dialysis facility center in Sun Lakes, Arizona and it has 16 dialysis stations. It is located in Maricopa county at 9666 E Riggs Rd Ste 143, Sun Lakes, AZ, 85248. You can reach out to the office of SUN Lakes Dialysis (FMC) at (480) 883-1301. This dialysis clinic is managed and/or owned by Fresenius Medical Care. SUN Lakes Dialysis (FMC) has the following ownership type - Profit. It was first certified by medicare in June, 1999. The medicare id for this facility is 032579 and it accepts patients under medicare ESRD program.
Name | SUN Lakes Dialysis (FMC) |
---|---|
Location | 9666 E Riggs Rd Ste 143, Sun Lakes, Arizona |
No. of Dialysis Stations | 16 |
Medicare ID | 032579 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
9666 E Riggs Rd Ste 143, Sun Lakes, Arizona, 85248 | |
(480) 883-1301 | |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
NPI Number | 1659483469 |
Organization Name | Renal Care Group Sun Lakes |
Doing Business As | Renal Care Group Arizona, Llc |
Address | 9666 E Riggs Rd Sun Lakes, Arizona, 85248 |
Phone Number | (480) 883-1301 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 59% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 27% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 14% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 52% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 33% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 14% |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 69% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 10% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 3% | 12% |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 83% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 17% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 73% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 2% | 12% |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
Dialysis patients with Hemoglobin data | 45 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 2 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 82 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 732 |
Percentage of adult patients getting regular hemodialysis at the center | 98 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at SUN Lakes Dialysis (FMC) with elevated calcium levels.
Patients with hypercalcemia | 85 |
Hypercalcemia patient months | 770 |
Patients with Serumphosphor | 92 |
Patients with Serumphosphor less than 3.5 mg/dL | 5 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 27 |
Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 83 |
Patient months included in arterial venous fistula and catheter summaries | 611 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 88 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 66 |
Hospitalization Rate in facility | 128.7 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 248.3 |
Hospitalization Rate: Lower Confidence Limit | 69.9 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at SUN Lakes Dialysis (FMC) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 21.5 (As Expected) |
Readmission Rate: Upper Confidence Limit | 35.4 |
Readmission Rate: Lower Confidence Limit | 11.2 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at SUN Lakes Dialysis (FMC) get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .66 (As Expected) |
SIR: Upper Confidence Limit | 1.79 |
SIR: Lower Confidence Limit | .17 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether SUN Lakes Dialysis (FMC)'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 50 |
Transfusion Rate in facility | 21.3 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 89.9 |
Transfusion Rate: Lower Confidence Limit | 6 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at SUN Lakes Dialysis (FMC) lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 285 |
Mortality Rate in facility | 17.8 (As Expected) |
Mortality Rate: Upper Confidence Limit | 25 |
Mortality Rate: Lower Confidence Limit | 12.2 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago
SUN Lakes Dialysis (FMC) Location: 9666 E Riggs Rd Ste 143, Sun Lakes, Arizona, 85248 Phone: (480) 883-1301 |
News Archive
In a breakthrough that may help fill a critical need in stem cell research and patient care, researchers at Mount Sinai School of Medicine have demonstrated that skin cells found in human amniotic fluid can be efficiently "reprogrammed" to pluripotency, where they have characteristics similar to human embryonic stem cells that can develop into almost any type of cell in the human body. The study is online now and will appear in print in the next issue of the journal Cellular Reprogramming, to be published next month.
A new study has found that the health needs of the Chinese population in the UK are being ignored despite Government commitments to tackle health inequalities amongst patients.
Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.
New research from the Advanced Gene and Cell Therapy Lab at Royal Holloway, University of London has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in Spinal Muscular Atrophy than others.
› Verified 1 days ago